While multiple mechanisms can mediate drug resistance development, FOXM1 is repeatedly identified as a common factor associated with weaker responses to conventional cancer therapies by regulating several target genes associated with cell cycle and DNA repair [3, 5, 18–24]. This evidence concerns the gene FOXM1 and cancer.